CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended			213 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013
Cash Flows From Operating Activities:
Net loss	$ (8,554,322)	$ (9,490,278)	$ (21,675,867)	$ (362,727,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	463,718	612,658	742,961	10,372,258
Minority interest share of loss				(3,038,185)
Reduction of notes receivable - common stock in exchange for services rendered				423,882
Write-off of uncollectible notes receivable - common stock				391,103
Write-off of deferred offering costs				3,406,196
Write-off of abandoned patents		440,780		1,353,976
(Gain)/loss on disposal of property and equipment	(1,037,485)	(2,027,939)	35,878	(3,028,635)
Loss on extinguishment of debt				14,134,068
Common stock issued as employee compensation				4,011,938
Amortization of options and option modifications as stock compensation	837,754	602,384	936,465	4,248,980
Common stock issued for services rendered	392,421	699,445	1,990,005	14,899,700
Amortization of prepaid services in conjunction with common stock issuance				138,375
Non-cash compensation expense				45,390
Stock options and warrants issued for services rendered				7,956,723
Issuance of warrants as additional exercise right inducement				21,437,909
Preferred stock issued for services rendered				100
Treasury stock redeemed for non-performance of services				(138,000)
Amortization of deferred debt issuance costs and loan origination fees				2,405,629
Amortization of discount on convertible debentures				38,345,592
Common stock issued for interest on convertible debentures & preferred stock	886,950	485,190		2,129,654
Interest on short-term advance				22,190
Founders' shares transferred for services rendered				353,506
Fees in connection with refinancing of debt				113,274
Warrant repricing costs				3,198,604
Change in fair value of derivative liabilities	3,140,259	1,081,440	(2,220,916)	3,856,236	[1]
Changes in operating assets and liabilities (excluding the effects of acquisition):
Accounts receivable		8,470	62,200	(15,047)
Miscellaneous receivables				(43,812)
Inventory		716,392	1,197,768	(20,091)
Other current assets	124,197	20,946	116,171	(58,751)
Accounts payable and accrued expenses	123,556	(1,218,616)	1,811,120	15,147,496
Deferred revenue	(38,282)	(105,395)	(28,152)	219,050
Other, net				110,317
Net Cash Used in Operating Activities	(3,661,234)	(8,043,979)	(16,931,368)	(220,260,632)
Cash Flows From Investing Activities:
Purchase of property and equipment		(2,416)	(52,383)	(4,809,439)
Proceeds from sale of property and equipment	1,764,008	4,953,325		6,717,333
Costs incurred for patents	(78,948)	(173,775)	(234,984)	(2,918,994)
Change in restricted cash				(512,539)
Proceeds from maturity of short term investments				195,242,918
Purchases of short-term investments				(195,242,918)
Cash received in conjunction with merger				82,232
Advances to Antigen Express, Inc.				(32,000)
Increase in officers' loans receivable				(1,126,157)
Change in deposits				(652,071)
Change in notes receivable - common stock				(91,103)
Change in due from related parties				(2,222,390)
Other, net				89,683
Net Cash Provided By (Used in) Investing Activities	1,685,060	4,777,134	(287,367)	(4,450,367)
Cash Flows From Financing Activities:
Proceeds from short-term advance				325,179
Repayment of short-term advance				(347,369)
Proceeds from issuance of long-term debt	829,038	3,561,688		6,396,335
Repayment of long-term debt	(1,833,265)	(4,821,511)	(116,632)	(8,895,964)
Repayment of obligations under capital lease			(7,818)	(83,002)
Change in due to related parties				154,541
Proceeds from exercise of warrants	1,845,204	30,000		47,573,485
Proceeds from exercise of stock options	5,181	1,300	577	5,008,974
Proceeds from minority interest investment				3,038,185
Proceeds from issuance of preferred stock	2,615,000	1,975,000	2,315,000	18,920,000
Redemption of SVR preferred stock				(100)
Proceeds from issuance of convertible debentures, net				40,704,930
Payment of costs associated with convertible debentures				(722,750)
Repayments of convertible debentures				(5,142,424)
Purchase of treasury stock				(483,869)
Proceeds from issuance of common stock, net			3,939,000	120,576,242
Purchase and retirement of common stock				(497,522)
Net Cash Provided by Financing Activities	3,461,158	746,477	6,130,127	226,524,871
Effect of Exchange Rates on Cash	(22,339)	(32,120)	6,535	(104,918)
Net (Decrease) Increase in Cash and Cash Equivalents	1,462,645	(2,552,488)	(11,082,073)	1,708,954
Cash and Cash Equivalents, Beginning of Period	246,309	2,798,797	13,880,870
Cash and Cash Equivalents, End of Period	$ 1,708,954	$ 246,309	$ 2,798,797	$ 1,708,954

[1] Includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to July 31, 2013" column. See Note 10 - Derivative Liabilities.